The Bridge from Bench to Bedside

Most preclinical drug candidates fail in clinical trials because the translation from animal models to humans was wrong. The CureForge Translational Medicine Institute is the federation’s research engine for fixing that. Ten specialized AI systems collaborate across cross-species pharmacokinetic and pharmacodynamic translation including mouse-to-human, dog-to-human, and primate-to-human, animalmodel selection across genetically engineered, humanized, and organoid alternatives, organoid-based translation through microphysiological systems, biomarker-driven progression decisions for Phase 1 to Phase 2 to Phase 3 transitions, target deconvolution in clinical samples, Phase 1 biomarker strategy, adaptive trial bridge work, federation-wide translational failure-pattern recognition, cross-vertical translation coordination, and adversarial review of every translation decision before clinical commitment.

Value proposition:

• Cross-species pharmacokinetic-pharmacodynamic translation as default rigor
• Biomarker-driven progression decisions across all clinical phases
• Federation-wide failure-pattern learning across all therapeutic programs